Skeletal Disease Drug Development Pipeline Review, 2017

Report Hive Market Research Released a New Research Report of 176 pages on Title " Skeletal Disease Drug Development Pipeline Review, 2017 "with detailed Analysis, Forecast and Strategies.

Skeletal Disease Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the skeletal disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA).

OA is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Postmenopausal osteoporosis is the most common subtype of osteoporosis, and affects many women after menopause. Signs and symptoms of osteoporosis include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and other osteoporosis medications.

The size of these pipelines ranges from 13 products in postmenopausal osteoporosis to 116 in OA. The predominant targets within OA are prostaglandin G/H synthases 1 and 2, although a wide range of targets, including extracellular matrix-organizing proteins and interleukins, are being studied. Likewise, within both osteoporosis and the post-menopausal subtype, a broad range of molecular targets are being studied. The targets being most frequently studied are the parathyroid hormone receptor, tumor necrosis factor ligand superfamily member 11 and sclerostin.

Request Free Research Sample: https://www.reporthive.com/request-sample.php?id=931460

Scope

- Which companies are the most active within the pipeline for osteoporosis and OA therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of osteoporosis and OA therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 9
Introduction 10
Skeletal Disease Report Coverage 10
Osteoarthritis - Overview 10
Osteoporosis - Overview 10
Post Menopausal Osteoporosis - Overview 10
Therapeutics Development 11
Osteoarthritis 11

Browse Full Report: https://www.reporthive.com/details/skeletal-disease-drug-development-pipeline-review-2017

Osteoporosis 21
Post Menopausal Osteoporosis 31
Therapeutics Assessment 34
Osteoarthritis 34
Osteoporosis 44
Post Menopausal Osteoporosis 54
Companies Involved in Therapeutics Development 62
Osteoarthritis 62
Osteoporosis 96

Key questions answered in the report

· What will the market size and the growth rate be in 2021?
· What are the key factors driving the Skeletal Disease Drug Development Market?
· What are the key market trends impacting the growth of the Skeletal Disease Drug Development Market?
· What are the challenges to market growth?
· Who are the key vendors in this market space?
· What are the market opportunities and threats faced by the vendors in the Skeletal Disease Drug Development Market?
· Trending factors influencing the market shares of the Americas, APAC, and EMEA?
· What are the key outcomes of the five forces analysis of the Skeletal Disease Drug Development Market?

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312-604-7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014

This release was published on openPR.